



5 **What is claimed is:**

1. A compound having the formula (I):



or a pharmaceutically acceptable salt or solvate thereof, wherein

- 10  $Ar^1$  and  $Ar^2$  are each independently selected from the group consisting of  $(R^{19})_{n7}$ -heteroaryl- and




$X^1$  is selected from the group consisting of -O-, -S-, -SO-, -SO<sub>2</sub>-, -NR<sup>12</sup>-, -N(COR<sup>12</sup>)- and -N(SO<sub>2</sub>R<sup>15</sup>)-;

- 15  $R^1$ ,  $R^3$  and  $R^5$  are each independently selected from the group consisting of H and C<sub>1</sub>-C<sub>6</sub> alkyl;


- $R^2$ ,  $R^4$  and  $R^6$  are each independently selected from the group consisting of H, -CONR<sup>13</sup>R<sup>14</sup> and -(CH<sub>2</sub>)<sub>n1</sub>-G; wherein G is selected from the group consisting of H, -CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -OH, -O-(C<sub>1</sub>-C<sub>6</sub>)alkyl, -SO<sub>2</sub>R<sup>13</sup>, -O-(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -NR<sup>13</sup>R<sup>14</sup>,  
20 -SO<sub>2</sub>NR<sup>13</sup>R<sup>14</sup>, -NR<sup>13</sup>SO<sub>2</sub>R<sup>15</sup>, -NR<sup>13</sup>COR<sup>12</sup>, -NR<sup>12</sup>(CONR<sup>13</sup>R<sup>14</sup>), -CONR<sup>13</sup>R<sup>14</sup>, -COOR<sup>12</sup> and C<sub>3</sub>-C<sub>8</sub> cycloalkyl; or

$R^1$  and  $R^2$ , taken together with the carbon to which they are attached, form a C<sub>3</sub>-C<sub>6</sub> cycloalkyl ring; or

$R^1$  and  $R^2$ , taken together with the carbon to which they are attached, form a




5 group, provided that X1 is -O- or -NR<sup>12</sup> when said




is formed; or

R<sup>3</sup> and R<sup>4</sup>, taken together with the carbon to which they are attached, form a



10 group; or

R<sup>5</sup> and R<sup>6</sup>, taken together with the carbon to which they are attached, form a



group;

15 R<sup>7</sup> and R<sup>11</sup> are each independently selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (R<sup>16</sup>)<sub>n7</sub>-aryl-, (R<sup>19</sup>)<sub>n7</sub>-heteroaryl-, -COOR<sup>29</sup>, -CONR<sup>21</sup>R<sup>22</sup>, -CON(R<sup>21</sup>)(CH<sub>2</sub>)<sub>n</sub>-G<sup>1</sup>, -S(O)<sub>n5</sub>(CH<sub>2</sub>)<sub>n</sub>-G<sup>1</sup>, -S(O)<sub>n5</sub>R<sup>13</sup>, -CO(CH<sub>2</sub>)<sub>n</sub>-G<sup>1</sup> and -(CH<sub>2</sub>)<sub>n1</sub>-G<sup>1</sup>; wherein


n is 0-4, and

20 G<sup>1</sup> is selected from the group consisting of H, -OH, (C<sub>1</sub>-C<sub>6</sub>)alkyl, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl), -S(O)<sub>n5</sub>R<sup>13</sup>, -O-(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -NR<sup>13</sup>R<sup>14</sup>, -SO<sub>2</sub>NR<sup>13</sup>R<sup>14</sup>, -NR<sup>13</sup>SO<sub>2</sub>R<sup>15</sup>, -NR<sup>13</sup>COR<sup>12</sup>, -NR<sup>12</sup>(CONR<sup>13</sup>R<sup>14</sup>), -OC(=O)R<sup>12</sup>, -CONR<sup>13</sup>R<sup>14</sup>, -COOR<sup>12</sup>, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -CF<sub>3</sub>, (R<sup>16</sup>)<sub>n7</sub>-aryl-O-, (R<sup>16</sup>)<sub>n7</sub>-aryl-, (R<sup>19</sup>)<sub>n7</sub>-heteroaryl-, (R<sup>19</sup>)<sub>n7</sub>-heterocycloalkyl- and alkenyl, and


25 provided that, when n is 0, then G<sup>1</sup> is selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, alkenyl, -CONR<sup>13</sup>R<sup>14</sup>, -COOR<sup>12</sup>, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -CF<sub>3</sub>, (R<sup>16</sup>)<sub>n7</sub>-aryl-, (R<sup>19</sup>)<sub>n7</sub>-heteroaryl-, and (R<sup>19</sup>)<sub>n7</sub>-heterocycloalkyl-; and

30 provided that, when n<sub>1</sub> is 1, then G<sup>1</sup> is selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, alkenyl, -S(O)<sub>n5</sub>R<sup>13</sup>, -SO<sub>2</sub>NR<sup>13</sup>R<sup>14</sup>,

- 5                    -CONR<sup>13</sup>R<sup>14</sup>, -COOR<sup>12</sup>, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -CF<sub>3</sub>, (R<sup>16</sup>)<sub>n7</sub>-aryl-,  
                      (R<sup>19</sup>)<sub>n7</sub>-heteroaryl- wherein said heteroaryl ring is bound by a ring carbon  
                      to the -(CH<sub>2</sub>)<sub>n1</sub>- group, and (R<sup>19</sup>)<sub>n7</sub>-heterocycloalkyl- wherein said  
                      heterocycloalkyl ring is bound by a ring carbon to the -(CH<sub>2</sub>)<sub>n1</sub>- group; or  
 10                    R<sup>7</sup> and R<sup>11</sup>, taken together with the nitrogen to which they are attached, form a  
                      5-7 membered heterocycloalkyl ring of the following formula:



R<sup>7</sup> and R<sup>11</sup>, taken together with the nitrogen to which they are attached, form a  
 5-membered ring having the formula (A) or (B):



- 15                    X is selected from the group consisting of -NR<sup>20</sup>-, -N(CONR<sup>13</sup>R<sup>14</sup>)-,  
                      -N(CO<sub>2</sub>R<sup>13</sup>)-, -N(SO<sub>2</sub>R<sup>15</sup>)-, -N(COR<sup>12</sup>)-, -N(SO<sub>2</sub>NHR<sup>13</sup>)-, -O-, -S-, -SO-, -SO<sub>2</sub>-, -CF<sub>2</sub>-,  
                      -CH<sub>2</sub>-, and -C(R<sup>12</sup>)F-;

- R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are each independently selected from the group consisting of H,  
                      C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -OR<sup>12</sup>, halogen, -CN, -NO<sub>2</sub>, -CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -OCF<sub>3</sub>,  
 20                    -OCHF<sub>2</sub>, -OCH<sub>2</sub>F, -COOR<sup>12</sup>, -CONR<sup>21</sup>R<sup>22</sup>, -NR<sup>21</sup>COR<sup>12</sup>, -NR<sup>21</sup>CO<sub>2</sub>R<sup>15</sup>,  
                      -NR<sup>21</sup>CONR<sup>21</sup>R<sup>22</sup>, -NR<sup>21</sup>SO<sub>2</sub>R<sup>15</sup>, -NR<sup>21</sup>R<sup>22</sup>, -SO<sub>2</sub>NR<sup>21</sup>R<sup>22</sup>, -S(O)<sub>n5</sub>R<sup>15</sup>, (R<sup>16</sup>)<sub>n7</sub>-aryl- and  
                      (R<sup>19</sup>)<sub>n7</sub>-heteroaryl-;

                     R<sup>12</sup> is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>3</sub>-C<sub>8</sub> cycloalkyl;

- R<sup>13</sup> and R<sup>14</sup> are each independently selected from the group consisting of H,  
 25                    C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>3</sub> alkyl-O-CH<sub>3</sub>, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (R<sup>19</sup>)<sub>n7</sub>-aryl(CH<sub>2</sub>)<sub>n6</sub>- and  
                      (R<sup>19</sup>)<sub>n7</sub>-heteroaryl-(CH<sub>2</sub>)<sub>n6</sub>-; or

5  $R^{13}$  and  $R^{14}$ , taken together with the nitrogen to which they are attached, form a 4-7 membered ring containing from 0-3 additional heteroatoms selected from the group consisting of -O-, -S- and -NR<sup>12</sup>-;

$R^{15}$  is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl or -CF<sub>3</sub>;

10  $R^{16}$  is 1 to 3 substituents each independently selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, halogen and -CF<sub>3</sub>;

$R^{19}$  is 1 to 3 substituents each independently selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -OH, halogen, -CN, -NO<sub>2</sub>, -C(O)CF<sub>3</sub>, -CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -OCF<sub>3</sub>, -OCHF<sub>2</sub>, -OCH<sub>2</sub>F, -O-(C<sub>1</sub>-C<sub>6</sub> alkyl), -O-(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -COOR<sup>12</sup>, -CONR<sup>21</sup>R<sup>22</sup>, -NR<sup>21</sup>R<sup>22</sup>, -NR<sup>21</sup>COR<sup>12</sup>, -NR<sup>21</sup>CO<sub>2</sub>R<sup>12</sup>, -NR<sup>21</sup>CONR<sup>21</sup>R<sup>22</sup>,  
15 -NR<sup>21</sup>SO<sub>2</sub>R<sup>15</sup> and -S(O)<sub>n5</sub>R<sup>15</sup>;


$R^{20}$  is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -(CH<sub>2</sub>)<sub>n6</sub>-heterocycloalkyl, (R<sup>19</sup>)<sub>n7</sub>-aryl(CH<sub>2</sub>)<sub>n6</sub>- or (R<sup>19</sup>)<sub>n7</sub>-heteroaryl-(CH<sub>2</sub>)<sub>n6</sub>-;

$R^{21}$  and  $R^{22}$  are each independently selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl and benzyl; or

20  $R^{21}$  and  $R^{22}$ , taken together with the nitrogen to which they are attached, form a 4-7 membered heteroaryl ring containing from 0-3 additional heteroatoms selected from the group consisting of -O-, -S- and -NR<sup>12</sup>-;

$R^{23}$  and  $R^{24}$  are each independently selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl and -CONR<sup>13</sup>R<sup>14</sup>; or


25  $R^{23}$  and  $R^{24}$ , taken together with the carbon atom to which they are attached, form a



group;

30  $R^{25}$ ,  $R^{26}$ ,  $R^{27}$  and  $R^{28}$  are each independently selected from the group consisting of H and C<sub>1</sub>-C<sub>6</sub> alkyl; or


$R^{25}$  and  $R^{26}$ , taken together with the carbon atom to which they are attached, form a



5

group; or

$R^{27}$  and  $R^{28}$ , taken together with the carbon atom to which they are attached, form a



10 group;

$R^{29}$  is selected from the group consisting of  $C_1$ - $C_6$  alkyl and  $C_3$ - $C_8$  cycloalkyl;

$n_1$  is 1-4;

$n_2$  and  $n_3$  are each independently 0-3, provided that a sum of  $n_2$  and  $n_3$  is 0-4;

$n_4$  is 0-2;

15

$n_5$  is 0-2;

$n_6$  is 0-3; and


$n_7$  is 0-3; and

provided that, when  $n_4$  is 0, and  $R^{25}$  and  $R^{26}$  are each H, then X is not -O-, -NR<sup>20</sup>- or -S-.

20

2. The compound of Claim 1 wherein  $X^1$  is -O-.


3. The compound of Claim 1 wherein  $Ar^1$  and  $Ar^2$  are each independently



25


4. The compound of Claim 3 wherein  $R^8$ ,  $R^9$  and  $R^{10}$  are each independently selected from the group consisting of H, -CH<sub>3</sub>, halogen and -CF<sub>3</sub>.

- 5            5.        The compound of Claim 1 wherein  
                        $X^1$  is -O-; and  
                        $Ar^1$  and  $Ar^2$  are each independently




- wherein  $R^8$ ,  $R^9$  and  $R^{10}$  are each independently selected from the group consisting of  
 10        H, -CH<sub>3</sub>, halogen and -CF<sub>3</sub>.

6.        The compound of Claim 1 wherein  
                        $Ar^1$  is



15

$Ar^2$  is




wherein,

- $R^8$  is selected from the group consisting of H and F, and  
 20                    $R^9$  and  $R^{10}$  are each independently selected from the group consisting of  
                       H, -CH<sub>3</sub>, F, Cl and -CF<sub>3</sub>.


7.        The compound of Claim 6 wherein  
                        $X^1$  is -O-; and  
 25                    $R^3$ ,  $R^4$ ,  $R^{27}$  and  $R^{28}$  are each H.

8.        The compound of Claim 6 wherein  $R^5$  and  $R^6$  are H.

- 5            9.        The compound of Claim 7 wherein  $R^7$  and  $R^{11}$ , taken together with the nitrogen to which they are attached, form a 5-7 membered ring having the following formula:















- 10            10.        The compound of Claim 1 having the formula



























wherein  $R^7$ ,  $R^8$  and  $R^{11}$  are selected from the group consisting of:








$R^8$	$R^7$	$R^{11}$
H	H	H
H	H	
H	H	
H	H	
H	H	

H	H	
H	H	
H	H	
H	H	
H	H	
H	H	
H	H	
H	H	
H	H	
H	H	
H	H	
H	H	




H	H	
H	H	
H	H	
H	H	
H	H	
H	H	
H	H	
H	H	
H	H	
H	H	
H	H	

H		
H		
F	H	
F	H	H
F	H	
F	H	
F	H	
F	H	
F	H	
F	H	
F	H	
H	H	

H	H	
F	H	
F	H	
H	H	
H	H	
H	H	
H	H	










5









11. The compound of Claim 1 having the formula:



wherein  $R^1$ ,  $R^2$ ,  $R^7$ ,  $R^8$  and  $R^{11}$  are selected from the group consisting of:






5

$R^8$	$R^1$	$R^2$	$-NR^7R^{11}$
H	H	H	
H	H	H	
H	H	H	
H	H	H	
F	H	H	
F	H	H	
F	H	H	
H	H	H	
H	H	CH <sub>3</sub>	

H	H	CH <sub>2</sub> OH	
H	H	H	
H	H	H	
H	H	H	
H	H	H	
H	H	H	
H	H	H	
H	H	H	


5

12. The compound of Claim 11 or the pharmaceutically acceptable salt or solvate thereof, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>11</sup> are selected from the group consisting of


$R^8$	$R^1$	$R^2$	$-NR^7R^{11}$
H	H	H	
H	H	H	
H	H	CH <sub>3</sub>	
H	H	CH <sub>2</sub> OH	
H	H	H	

5

13. The compound of Claim 12 having the formula:




15. The compound of Claim 12 having the formula:



10

OC[C@H](c1ccc(C(F)(F)F)cc1)OCC1(c2ccccc2)C2CCN(C2)C3CCCC3=O

- 5            17.    The compound of Claim 12 having the formula:



18.    A pharmaceutical composition comprising at least one compound of Claim 1, and a pharmaceutically acceptable carrier.

10

19.    A pharmaceutical composition comprising a pharmaceutically acceptable carrier, at least one serotonin reuptake inhibitor, and at least one compound of Claim 1.

15

20.    A method for treating a physiological disorder, symptom or disease in a patient in need of such treatment, comprising administering to said patient an effective amount of at least one compound of Claim 1, wherein said physiological disorder, symptom or disease is selected from the group consisting of: respiratory diseases, inflammatory diseases, skin disorders, ophthalmological disorders, central nervous system conditions, addictions, epilepsy, nociception, psychosis, schizophrenia, Alzheimer's disease, AIDs related dementia, Towne's disease, stress related disorders, obsessive/compulsive disorders, eating disorders, sleep disorders, mania, premenstrual syndrome, gastrointestinal disorders, atherosclerosis, fibrosing disorders, obesity, Type II diabetes, pain related disorders, bladder and genitourinary disorders, and nausea.

25

21.    A method for treating a physiological disorder, symptom or disease in a patient in need of such treatment, comprising administering to said patient an effective



5 amount of at least one compound of Claim 1, wherein said physiological disorder,  
symptom or disease is selected from the group consisting of: a respiratory disease,  
depression, anxiety, phobia, bipolar disorder, alcohol dependence, psychoactive  
substance abuse, nociception, psychosis, schizophrenia, stress related disorder,  
obsessive/compulsive disorder, bulimia, anorexia nervosa, binge eating, sleep  
10 disorder, mania, premenstrual syndrome, gastrointestinal disorder, obesity, headache,  
neuropathic pain, post-operative pain, chronic pain syndrome, bladder disorder,  
genitourinary disorder, cough, emesis and nausea.

22. A method for treating a physiological disorder, symptom or disease in a  
15 patient in need of such treatment, comprising administering to said patient an effective  
amount of at least one compound of Claim 1, and an effective amount of at least one  
active ingredient selected from the group consisting of: other NK<sub>1</sub> receptor  
antagonists, selective serotonin reuptake inhibitors, dopamine receptor agonists,  
serotonin 5-HT<sub>3</sub> receptor antagonists, serotonin 5-HT<sub>2c</sub> receptor agonists, nociceptin  
20 receptor agonists, glucocorticoids and inhibitors of multidrug resistance protein 5,  
wherein said physiological disorder, symptom or disease is selected from the group  
consisting of: a respiratory disease, depression, anxiety, phobia, bipolar disorder,  
alcohol dependence, psychoactive substance abuse, nociception, psychosis,  
schizophrenia, stress related disorder, obsessive/compulsive disorder, bulimia,  
25 anorexia nervosa, binge eating, sleep disorder, mania, premenstrual syndrome,  
gastrointestinal disorder, obesity, headache, neuropathic pain, post-operative pain,  
chronic pain syndrome, bladder disorder, genitourinary disorder, cough, emesis and  
nausea.

30 23. A method of treating emesis and/or nausea in a patient in need of such  
treatment comprising administering to said patient an effective amount of at least one  
compound having the formula (I) in combination with an effective amount of at least  
one serotonin 5-HT<sub>3</sub> receptor antagonist and/or at least one glucocorticoid.

5        24.    The method of Claim 23 wherein said serotonin 5-HT<sub>3</sub> receptor antagonist is ondansetron and said glucocorticoid is dexamethasone.

25.    The method of Claim 21, wherein the physiological disorder, symptom or disease is emesis, depression, anxiety or cough.

10        26.    The method of Claim 25 wherein the physiological disorder, symptom or disease is depression or anxiety.

15        27.    The method of Claim 26, further comprising administering to the patient an effective amount of at least one anti-depressant agent and/or at least one anti-anxiety agent.

20        28.    The method of Claim 25 wherein depression is being treated and said method further comprises administering to the patient an effective amount of at least one selective serotonin reuptake inhibitor.

25        29.    A method for antagonizing an effect of a Substance P at a neurokinin-1 receptor site or for blocking at least one neurokinin-1 receptor, in a patient in need of such treatment, comprising administering to said patient an effective amount of at least one compound of Claim 1.

30        30.    A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat an NK<sub>1</sub> receptor mediated disease, wherein one container comprises a pharmaceutical composition comprising an effective amount of a compound of Claim 1 in a pharmaceutically acceptable carrier, and wherein, a separate container comprises a pharmaceutical composition comprising another therapeutic agent in a pharmaceutically acceptable carrier, said therapeutic agent being selected from the group consisting of: SSRIs, other types of NK<sub>1</sub> receptor antagonists, prostanoids, H<sub>1</sub> receptor antagonists,  $\alpha$ -

5     adrenergic receptor agonists, dopamine receptor agonists, melanocortin receptor  
agonists, endothelin receptor antagonists, endothelin converting enzyme inhibitors,  
angiotensin II receptor antagonists, angiotensin converting enzyme inhibitors, neutral  
metalloendopeptidase inhibitors, ET<sub>A</sub> antagonists, renin inhibitors, serotonin 5-HT<sub>3</sub>  
10     receptor antagonists, serotonin 5-HT<sub>2c</sub> receptor agonists, nociceptin receptor  
agonists, glucocorticoids, rho kinase inhibitors, potassium channel modulators and  
inhibitors of multi-drug resistance protein 5.

31.     A kit comprising, in separate containers in a single package,  
pharmaceutical compositions for use in combination to treat depression and/or  
15     anxiety, wherein one container comprises a pharmaceutical composition comprising  
an effective amount of a compound of Claim 1 in a pharmaceutically acceptable  
carrier, and wherein, a separate container comprises a pharmaceutical composition  
comprising an antidepressant agent in a pharmaceutically acceptable carrier, and/or  
wherein a separate container comprises a pharmaceutical composition comprising an  
20     antianxiety agent in a pharmaceutically acceptable carrier.

32.     A kit comprising, in separate containers in a single package,  
pharmaceutical compositions for use in combination to treat an NK<sub>1</sub> receptor  
mediated disease, wherein one container comprises a pharmaceutical composition  
25     comprising an effective amount of a compound of Claim 1 in a pharmaceutically  
acceptable carrier, and wherein, a separate container comprises a pharmaceutical  
composition comprising an SSRI in a pharmaceutically acceptable carrier.

33.     A kit comprising, in separate containers in a single package,  
30     pharmaceutical compositions for use in combination to treat depression and/or  
anxiety, wherein one container comprises a pharmaceutical composition comprising  
an effective amount of a compound of Claim 1 in a pharmaceutically acceptable  
carrier, and wherein, a separate container comprises a pharmaceutical composition  
comprising an SSRI in a pharmaceutically acceptable carrier.

5

34. A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat emesis and/or nausea, wherein one container comprises a pharmaceutical composition comprising an effective amount of a compound of Claim 1 in a pharmaceutically acceptable carrier, and wherein, a separate container comprises a pharmaceutical composition comprising a serotonin 5-HT<sub>3</sub> receptor antagonist in a pharmaceutically acceptable carrier, and/or wherein a separate container comprises a pharmaceutical composition comprising a glucocorticoid in a pharmaceutically acceptable carrier.

10

15

35. A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat emesis and/or nausea, wherein one container comprises a pharmaceutical composition comprising an effective amount of a compound of Claim 1 in a pharmaceutically acceptable carrier, and wherein, a separate container comprises ondansetron, and/or wherein a separate container comprises dexamethasone.

20